Natural killer cell immunotypes related to COVID-19 disease severity.

Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group. · 2020

Read Natural killer cell immunotypes related to COVID-19 disease severity. by Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7665314.txt.

Introduction

Maucourant and co-authors study natural killer cells in acute COVID-19. Natural killer cells are fast-acting immune cells that kill infected cells. They also shape later T cell responses. Little was known about how they behave early in this infection.

The team mapped how these cells switch on during SARS-CoV-2 infection. They found distinct patterns of cell traits, which they call immunotypes. These patterns tracked with how severe the disease became. The work links early innate responses to disease course. It adds a piece to the puzzle of why some patients crash while others stay mild.

Catalog record

CREATORMaucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7665314

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Natural killer cell immunotypes related to COVID-19 disease severity By Christopher Maucourant, Iva Filipovic, Andrea Ponzetta, Soo Aleman, Martin Cornillet, Laura Hertwig, Benedikt Strunz, Antonio Lentini, Björn Reinius, Demi Brownlie, Angelica Cuapio, Eivind Heggernes Ask Published in: Science Immunology DOI: 10.1126/sciimmunol.abd6832 ABSTRACT The NK cell activation landscape in acute SARS-CoV-2 infection is associated with COVID-19 disease severity. INTRODUCTION The ongoing SARS-CoV-2 pandemic is presenting the human population with profound challenges. SARS-CoV-2 can cause coronavirus disease 2019 (COVID-19) disease, which, in the worst cases, leads to severe manifestations such as acute respiratory distress syndrome, multi-organ failure, and death (1). These manifestations may be caused by hyperactivated and misdirected immune responses. High levels of interleukin-6 (IL-6) and an ensuing cytokine storm in the absence of appropriate type I and III interferon responses associate with severe COVID-19 disease (1–6). Whereas emerging reports suggest that protective immunity is formed in convalescent patients with both neutralizing antibodies and SARS-CoV-2–specific T cells (7–9), considerably less is known about early innate lymphocyte responses toward the SARS-CoV-2 infection and how they relate to host responses and disease progression. In this study, we evaluated natural killer (NK) cell activation in the context of SARS-CoV-2 infection and resulting COVID-19 disease. NK cells are innate effector lymphocytes that are typically divided into cytokine-producing CD56bright NK cells and cytotoxic CD56dim NK cells (10). Evidence for a direct role of NK cells in protection against viral infections comes from patients with selective NK cell deficiencies, as these develop fulminant viral infections, predominantly with herpes viruses (11, 12). Human NK cells have also been shown to rapidly respond during the acute phase of infections in humans with hantavirus, tick-borne encephalitis virus, influenza A virus (IAV), and dengue virus, as well as after vaccination with live-attenuated yellow fever (13–16). NK cells not only have the capacity to directly target and kill infected cells but also can influence adaptive T cell responses. The degree of NK cell activation can function as a rheostat in regulating T cells, where a certain level of NK cell activation might promote infection control, while another degree of activation is related to immunopathology (17). Compared with peripheral blood, the human lung is enriched in NK cells (16, 18, 19). Human lung NK cells display a differentiated phenotype and also have the capacity to respond to viral infections such as IAV (16, 18, 19). In COVID-19, emerging studies have reported low peripheral blood NK cell numbers in patients with moderate and severe disease (4, 20–23). Two recent reports assessing the single-cell landscape of immune cells in bronchoalveolar lavage (BAL) fluid of COVID-19 patients have suggested that NK cell numbers are increased at this site of infection (24, 25). However, a detailed map of the NK cell landscape in clinical SARS-CoV-2 infection has not yet been established. Given the important role of NK cells in acute viral infections, their relatively high presence within lung tissue, as well as the links between NK cell activation, T cell responses, and development of immunopathology, we here performed a detailed assessment of NK cells in patients with moderate and severe COVID-19 disease. Using strict inclusion and exclusion criteria, patients with moderate and severe COVID-19 disease were recruited early during their disease, sampled for peripheral blood, and analyzed by 28-color flow cytometry to assess NK cell activation, education, and presence of adaptive NK cells. The results obtained are discussed in relation to the role of NK cell responses in acute SARS-CoV-2 infection and associated COVID-19 disease immunopathogenesis. RESULTS Study design, clinical cohort, and general NK cell activation in COVID-19 Twenty-seven in-hospital patients with COVID-19 disease (10 moderate and 17 severe) were prospectively recruited after admission to the Karolinska University Hospital as part of a larger immune cell atlas effort (Karolinska COVID-19 Immune Atlas). Strict inclusion and exclusion criteria were used to ensure the setup of homogeneous patient cohorts, including time since symptom debut in relation to hospital admission, and disease severity staging (Fig. 1, A and B). Seventeen healthy controls that were SARS-CoV-2 immunoglobulin G (IgG) seronegative and symptom-free at time of sampling were included as controls. To minimize inter-experimental variability and batch effects between patients and controls, all samples (n = 44) were acquired, processed, and analyzed fresh during three consecutive weeks in April and May 2020 at the peak of the COVID-19 pandemic in Stockholm, Sweden (Fig. 1B). More detailed patient characteristics are provided in Materials and Methods and tables S1 and S2. [Figure: NK cells are robustly activated in moderate and severe COVID-19 disease.(A) Schematic overview of study design, inclusion, and exclusion criteria. (B) Swimmer plot of symptom debut, hospital admission, and blood sampling in relation to other main clinical events and clinical characteristics. (C) Percentages and absolute counts of NK cells and NK cell subsets for healthy controls (n = 17), moderate COVID-19 patients (n = 10), and severe COVID-19 patients (n = 15 to 16). (D) Flow cytometry plots of Ki-67, HLA-DR, and CD69 expression on NK cells in one healthy control and one COVID-19 patient. (E and F) Summary data for expression of the indicated markers in (E) CD56bright and (F) CD56dim NK cells in healthy controls, moderate COVID-19 patients, and severe COVID-19 patients. (G) Flow cytometry plots of NKG2A, CD57, and CD62L expression on CD56dim NK cells. (H) Summary data for Ki-67, HLA-DR, and CD69 expression within NKG2A+/−, CD57+/−, or CD62L+/− CD56dim NK cells from all moderate and severe COVID-19 patients (n = 24 to 26). In (C) and (E), Kruskal-Wallis test and Dunn’s multiple comparisons test; in (H), Wilcoxon matched-pairs signed rank test. Numbers in flow cytometry plots indicate percentage, and bars represent median (*P < 0.05, **P < 0.01, and ***P < 0.001).] To study the NK cell response, we analyzed peripheral blood mononuclear cells (PBMCs) with a 28-color NK cell–focused flow cytometry panel (table S3, gating strategy in fig. S1A). No change in total NK cell percentages, or the percentage of CD56dim and CD56bright NK cells, was noted in patients compared with controls. However, the absolute counts of total NK cells, CD56dim NK cells, and CD56bright NK cells were severely reduced in patients compared with controls (Fig. 1C and fig. S1A). NK cell activation was assessed by analyzing expression of Ki-67, HLA-DR (human leukocyte antigen-DR), and CD69 (Fig. 1D). A robust NK cell activation was noted in COVID-19 patients, where the degree of activation was similar in moderate and severe patients (Fig. 1, E and F). CD56dim NK cells undergo continuous differentiation starting from less differentiated NKG2A+ and CD62L+ cells transitioning toward more terminally differentiated CD57+ NK cells (26, 27). A higher percentage of both NKG2A+ and CD62L+ CD56dim NK cells expressed Ki-67 compared with NKG2A− and CD62L− cells in patients with COVID-19 (Fig. 1, G and H). A subsequent Boolean analysis, simultaneously taking coexpression patterns of NKG2A, CD62L, and CD57 into account, revealed that the NK cell response in patients with COVID-19 occurred primarily among less differentiated CD62L+ NK cells (fig. S1B). Together, using strict inclusion and exclusion criteria and patient recruitment during a defined period of time, we obtained a well-controlled cohort of patients with moderate and severe COVID-19. Peripheral blood NK cells in these patients were robustly activated compared with healthy controls. The general degree

Read the complete text